ZA9710114B - Method for the expression of genes. - Google Patents

Method for the expression of genes.

Info

Publication number
ZA9710114B
ZA9710114B ZA9710114A ZA9710114A ZA9710114B ZA 9710114 B ZA9710114 B ZA 9710114B ZA 9710114 A ZA9710114 A ZA 9710114A ZA 9710114 A ZA9710114 A ZA 9710114A ZA 9710114 B ZA9710114 B ZA 9710114B
Authority
ZA
South Africa
Prior art keywords
genes
expression
Prior art date
Application number
ZA9710114A
Other languages
English (en)
Inventor
Abderrahim Mahfoudi
Didier Branellec
Nicolas Duverger
Johan Auwerx
Patric Benoit
Patrice Denefle
Laurence Berthou
Bart Staels
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA9710114B publication Critical patent/ZA9710114B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA9710114A 1996-11-08 1997-11-10 Method for the expression of genes. ZA9710114B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9613691A FR2755699B1 (fr) 1996-11-08 1996-11-08 Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes

Publications (1)

Publication Number Publication Date
ZA9710114B true ZA9710114B (en) 1998-06-08

Family

ID=9497481

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710114A ZA9710114B (en) 1996-11-08 1997-11-10 Method for the expression of genes.

Country Status (15)

Country Link
US (1) US20020144302A1 (ja)
EP (1) EP0946740A1 (ja)
JP (1) JP2001503279A (ja)
KR (1) KR20000053163A (ja)
AU (1) AU5057898A (ja)
BR (1) BR9713981A (ja)
CA (1) CA2269864A1 (ja)
CZ (1) CZ163399A3 (ja)
FR (1) FR2755699B1 (ja)
HU (1) HUP9904235A3 (ja)
IL (1) IL129593A0 (ja)
NO (1) NO992153D0 (ja)
SK (1) SK61499A3 (ja)
WO (1) WO1998021349A1 (ja)
ZA (1) ZA9710114B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
NZ516678A (en) * 1999-06-22 2004-04-30 Aventis Pharma Sa Regulation system of expression using nuclear PPAR receptors
FR2795425B1 (fr) * 1999-06-22 2003-12-05 Aventis Pharma Sa Systeme de regulation pharmacologique de l'expression utilisant les recepteurs nucleaires par et leurs ligands
FR2806418B1 (fr) * 2000-03-14 2004-07-16 Aventis Pharma Sa Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations
WO2001068845A2 (fr) * 2000-03-14 2001-09-20 Universite Pierre Et Marie Curie Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations
EP1288303A1 (en) * 2001-08-23 2003-03-05 Aventis Pharma S.A. Inducible expression systems employing PPAR transcriptional activators
AU2002333682A1 (en) * 2001-08-02 2003-02-17 Gencell S.A. Inducible expression systems employing ppar transcriptional activators
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0516443A1 (en) * 1991-05-31 1992-12-02 Eli Lilly And Company Vectors and methods for assaying the regulation of apolipoprotein ai synthesis
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2718329B1 (fr) * 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation

Also Published As

Publication number Publication date
BR9713981A (pt) 2000-05-02
WO1998021349A1 (fr) 1998-05-22
NO992153L (no) 1999-05-04
CZ163399A3 (cs) 1999-08-11
JP2001503279A (ja) 2001-03-13
IL129593A0 (en) 2000-02-29
KR20000053163A (ko) 2000-08-25
CA2269864A1 (fr) 1998-05-22
NO992153D0 (no) 1999-05-04
SK61499A3 (en) 2000-02-14
HUP9904235A2 (hu) 2000-04-28
HUP9904235A3 (en) 2003-03-28
AU5057898A (en) 1998-06-03
US20020144302A1 (en) 2002-10-03
FR2755699A1 (fr) 1998-05-15
EP0946740A1 (fr) 1999-10-06
FR2755699B1 (fr) 1998-12-18

Similar Documents

Publication Publication Date Title
ZA967315B (en) Biphenylamides.
ZA977948B (en) Process for the control of weeds.
MX213417B (es) Fenilpiridazinonas.
ZA976559B (en) Method for activation of bleaches.
ZA9710322B (en) Process for the preparation of benzyl-ethers.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA961955B (en) Indazolecarboxamides.
ZA976733B (en) Hydrotreating process.
ZA971272B (en) Gene expression.
ZA979286B (en) Method of controlled blasting.
ZA964319B (en) Spectroscopic method.
DE69610844D1 (en) Hydroformylierungsverfahren.
ZA969016B (en) Solubilisation methods.
ZA9710114B (en) Method for the expression of genes.
ZA972061B (en) New method.
ZA966603B (en) Therapeutic method.
CY2392B1 (en) Method for the preparation of alpha-bromolactam derivatives.
EP0669361A3 (en) Process for the preparation of polyheterosiloxanes.
ZA966399B (en) Endothelin-receptor-antagonists.
ZA973400B (en) Method for the manufacture of brushes.
ZA982255B (en) Process for the preparation of arylmalonates.
ZA9710349B (en) Process for making benzisothiazolin-3-ones.
HK1030422A1 (en) Method for preparing oxazaphosphorin-2-amines.
ZA975637B (en) Method for the treatment of emesis.
ZA966933B (en) Endothelin-receptor-antagonists.